Volume 17, Number 8—August 2011
Research
Cost-effectiveness of Sick Leave Policies for Health Care Workers with Influenza-like Illness, Brazil, 2009
Nancy Val y Val P. Mota, Renata D. Lobo, Cristiana M. Toscano, Antonio C. Pedroso de Lima, M. Beatriz Souza Dias, Helio Komagata, and Anna S. Levin
Table 1
Evaluation of the effect of ILI-associated absenteeism among HCWs during the pandemic (H1N1) 2009 outbreak, Hospital das Clínicas, São Paulo, Brazil, May–October 2009*
| Input | Value | Data source | Assumptions |
||
|---|---|---|---|---|---|
| Baseline cost | Lowest cost scenario | Highest cost scenario | |||
| No. physicians, nurses, and nurse assistants receiving ILI-associated sick leave |
415 for 2-d + reassessment; 169 for 7-d |
Centralized occupational health database |
NA |
NA |
NA |
| Costs | |||||
| Medical consultation | R$7.90/ consultation | National Health Care System | 1.1 consultations/ HCW for 7-d; 2.5/HCW for 2-d + reassessment | 1 consultation/HCW for 7-d; 1.5/HCW for 2-d + reassessment | 2.5 consultations/HCW for 7-d; 4/HCW for 2-d + reassessment |
| Transportation for consultation | R$10.00/round trip | Public transport fare | 10% returned for consultation for 7-d 1.5 returns/HCW for 2-d + reassessment | No return visits for 7-d; 0.5 returns/HCW for 2-d + reassessment | 1.5 returns for consultations for 7-d; 3 return visits for 2-d + reassessment |
| Oseltamivir treatment | R$112.40/ treatment | Central pharmacy | Received by 100% of HCWs with suspected influenza | Received by 100% of HCWs with suspected influenza | Received by 100% of HCWs with suspected influenza |
| Amoxicillin treatment | R$2.40/ treatment | Central pharmacy | Received by 20% of HCWs with suspected influenza. | Received by 5% of HCWs with suspected influenza | Received by 60% of HCWs with suspected influenza |
| Medication for symptoms | R$2.95/ treatment | Central pharmacy | Received by 70% of HCWs with suspected influenza | Received by 20% of HCWs with suspected influenza | Received by 100% of HCWs with suspected influenza |
| Diagnostic rt-PCR† | R$100.00/test | Central laboratory | NA | NA | NA |
| Swab for collecting
specimen for rt-PCR |
R$0.46/test |
Central laboratory |
NA |
NA |
NA |
| No. HCWs undergoing diagnostic rt-PCR† | 244 | Central laboratory | NA | NA | NA |
| No. HCWs hospitalized† | None | Nucleus of Information on Health Care | NA | NA | NA |
| No. d hospitalization of HCWs† |
30 d for 2-d + reassessment; 4 d for 7-d |
Direct review of patient records |
NA |
NA |
NA |
| Daily cost | |||||
| Hospitalization | R$1,196.39 for 2-d + reassessment; R$1,871.06 for 7-d | Administration | |||
| Staff replacement | Nurse: R$257.07; nurse assistant: R$167.09; physician: R$858.51 | Human resource department | 70% of nurses, 70% of nurse assistants, 50% of physicians replaced | 30% of nurses, 30% of nurse assistants, 10% of physicians replaced | 100% of nurses, 100% of nurse assistants, 80% of physicians replaced |
| Productivity losses | Nurse: R$307.15; nurse assistant: R$157.18; physician: R$381.23 | Human resource department | NA | NA | NA |
*ILI, influenza-like illness; HCW, health care worker; 2-d + reassessment, 2-day sick leave plus reassessment every 2 days until asymptomatic policy; 7-d, 7-day sick leave policy; NA, not applicable; R$, Brazilian reals (R$1.80 = US $1.00); rt-PCR, real-time PCR.
†For pandemic (H1N1) 2009.
Page created: August 15, 2011
Page updated: August 15, 2011
Page reviewed: August 15, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.